Inari Medical, Inc. revised revenue guidance for the full year 2022. For the full year 2022, the company revising its revenue guidance to a range of $360 million to $370 million, an increase of $10 million from its original guidance range of $350 million to $360 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.95 USD | +5.29% | +9.18% | -23.06% |
23/05 | Sector Update: Health Care Stocks Lower Thursday Afternoon | MT |
23/05 | Inari Medical Sues Imperative Care, Truvic Medical for Alleged Patent Infringement | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.06% | 290.4Cr | |
+75.35% | 1.25TCr | |
-23.01% | 750.72Cr | |
+8.35% | 674.19Cr | |
+14.40% | 547.33Cr | |
-14.85% | 488.61Cr | |
+32.74% | 473.87Cr | |
+55.06% | 249.12Cr | |
+0.25% | 199.25Cr | |
+0.70% | 180.72Cr |
- Stock Market
- Equities
- NARI Stock
- News Inari Medical, Inc.
- Inari Medical, Inc. Revises Revenue Guidance for the Full Year 2022